New Target for Crohn's Disease Treatment Identified

Promising new target for future drugs to treat inflammatory bowel disease (IBD) has been discovered by a research team.

Promising new target for future drugs to treat inflammatory bowel disease (IBD) has been discovered by Sanford Burnham Prebys Medical Discovery Institute (SBP)scientists.

The study, published today in Cell Reports, also indicates that another protein, protein kinase C (PKC) λ/ι, may serve as a biomarker of IBD severity.

Crohn’s Disease
Crohn’s disease or regional enteritis is an inflammatory bowel disease that involves the small intestine and causes abdominal pain, diarrhea and bleeding.

‘EZH2 inhibitors offer hope for patients with irritable bowel disorders which include Crohn’s disease and ulcerative colitis, affect 1.4 million people in the U.S.’

“The intestine is protected by specialized cells, called Paneth cells, that secrete antimicrobial peptides,” said Jorge Moscat, Ph.D., deputy director and professor in the NCI-designated Cancer Center and senior author of the paper. “We found that maintaining normal numbers of Paneth cells requires PKC λ/ι, and that the amount of PKC λ/ι decreases as IBD gets worse. We also discovered a way to prevent Paneth cell loss—inhibiting a protein called EZH2, which could be a new therapeutic strategy for IBD.”

IBD, which includes Crohn’s disease and ulcerative colitis, affects 1.4 million people in the U.S. These chronic conditions are often debilitating, as they cause unpredictable abdominal pain and diarrhea. Because current medications only help control symptoms and not the underlying disease, 70% of Crohn’s patients and 30% of those with colitis must eventually undergo surgery. In addition, IBD increases risk of intestinal cancer by as much as 60%.

“We also examined the effect of PKC λ/ι on tumor formation,” said Maria Diaz-Meco, Ph.D., also a professor in the Cancer Center and co-author of the paper. “In contrast to some previous studies indicating that it might promote cancer development, we demonstrate that in the intestine, PKC λ/ι is protective.”

Quiz on Irritable Bowel Syndrome
Frequent bowel disturbances are a sign of possible cancerous changes; Here's a quiz to help you to brush up your knowledge on irritable bowel disorder.

“We inactivated the PKC λ/ι gene in the intestine of mice, which caused them to have very few Paneth cells,” added Diaz-Meco. “Without Paneth cells, the intestine is more susceptible to bacterial infiltration, which leads to inflammation. Since inflammation favors cancer, it makes sense that PKC λ/ι is a tumor suppressor in this setting.”

To find a way to boost Paneth cell numbers and possibly treat IBD, the team looked for what drives the deficit in these protector cells. The key link was overactive EZH2, which turns off genes needed to generate Paneth cells.

Smoking Causes Relapse Of Crohn�s Disease After Surgery
Crohn’s patients who continue to smoke after surgery are more likely to experience a relapse of the condition.

“We used an in vitro model—‘mini guts’ in a dish—to show that blocking EZH2 helps return the number of Paneth cells to normal,” said Yuki Nakanishi, M.D., a postdoctoral fellow in the Moscat/ Diaz-Meco lab and lead author of the work. “This demonstrates that inhibiting EZH2 could be a new way to slow the progression of IBD.”

Importantly, the team verified the relevance of their findings in intestinal biopsy samples from 30 patients with Crohn’s disease. Disease progression correlated with lower levels of PKC λ/ι.

Genetic Variants Prevent Good Gut Bacteria from Working In Patients With Crohn's Disease
A major type of inflammatory bowel disease (IBD) may be caused in part by genetic variants that prevent beneficial bacteria in the gut from doing their job.

“EZH2 inhibitors are currently being developed by the pharmaceutical industry to treat other cancers, so they could be tested for IBD relatively soon,” said Moscat. “But first, we need to do preclinical studies to test whether they block progression of the disease.”

This research was performed in collaboration with scientists at the University of California, Riverside, the University of Oslo, the Hyogo College of Medicine, Nishinomiya, Japan; and Brigham and Women’s Hospital, Harvard Medical School. Funding was provided by the National Institutes of Health and the Crohn’s & Colitis Foundation of America.

Source-Newswise